Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best small cap stocks to buy with huge upside potential. Barclays lifted the price target on Celldex Therapeutics, Inc. (NASDAQ:CLDX) to $24 from $21 on December 17 and reaffirmed an Equal Weight rating on the stock. The firm told investors that it adjusted the price targets in the biotechnology space to take into account its 2026 outlook. Is Celldex Therapeutics, Inc. (CLDX) the Best Cancer Stock to Invest in for Long-Term Gain? In a separate develo ...